SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

: Evolving Strategies in IBD: Targeting Learning to Close Gaps and Improve Outcomes
Activity/Course #:
: RealCME723150
: Free
Release/Start Date:
: Oct 18 2016
Expiration Date:
: Oct 17 2017
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: Patient Case Study
Estimated Time To Complete CME Activity:
: 0.50 Hours
: 0.50 AMA PRA Category I Credit(s) ™ / AAFP Prescribed Credits
0.5 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
Hardware/Software Requirements:
(Chrome not supported at this time)

Inflammatory bowel disease (IBD) is a term that encompasses chronic inflammatory disorders of the bowel, the most common of these being ulcerative colitis (UC) and Crohn's disease (CD). As many as 1.5 million persons in the United States may suffer from IBD accounting for over 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 patients every year in the United States. IBD is associated with an overall health care cost of more than $1.7 billion and adversely affects the quality of life of both patients and their families.

Several diseases may mimic IBD clinically, and careful and repeated evaluations, as necessary, can reduce the likelihood of misdiagnosis. Even if clinical, radiographic, endoscopic, and histologic criteria are applied, the diagnosis of UC and CD is in doubt in 15% of the cases at initial presentation. In patients with UC having colectomy and ileal-pouch anal anastomosis, the diagnosis is subsequently changed to CD in 3% to 7% of the cases. Providing medical care for IBD patients can be complex, requiring strategies for inducing and maintaining disease remission as well as monitoring for intestinal and extraintestinal complications of the diseases and prescribed therapies. Standardized algorithms on care for IBD patients do not exist, resulting in variations in the quality of care, which include underuse, overuse, or misuse of medical services.

This program will help to bridge the knowledge and performance gaps related to identification, and management of Inflammatory Bowel Disease. This educational initiative offers a two-phased curriculum. Phase 1 will offer a Self Assessment Program (SAP) to allow learners to assess their knowledge and skills in this area, compare their selections and scores with all other learners to date, and review commentary from the faculty. The goal of the SAP is to make learners aware of their strengths and weaknesses in this subject area.

A second activity utilizing a case-based interactive structure will be developed in Phase 2 focused on these drivers. This two-phased approach incorporating these statistical techniques will not only provide the stakeholders of this curriculum with the guidance to create an activity that will have optimal impact on clinical behavior, but will significantly impact the development of future curricula as well.

Learning Objectives

After completing this activity, the reader should be better able to:

  1. Recognize the conditions referred to as inflammatory bowel disease (IBD), and evaluate the degree of severity based on clinical measures of disease activity.
  2. Match appropriate pharmacologic therapeutic strategies to clinical IBD presentations to maximize outcomes while minimizing toxicity.
  3. Identify patients who are at high risk of complications from IBD and who may benefit from new mechanisms of action in IBD therapy.
  4. Employ approaches to optimize benefits from IBD treatment options and facilitate adherence

How To Obtain Your CME Certificate

  1. Read the learning objectives and faculty disclosures.
  2. Participate in the activity.
  3. Complete the post-test and activity evaluation.
  4. Physicians who successfully complete the post-test and evaluation will receive CME credit.
  5. Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
  6. You must score 60% or higher on the post-test to receive credit for this activity.
  7. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This Enduring Material activity, Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease: Targeting Learning to Close Gaps and Improve Outcomes, has been reviewed and is acceptable for prescribed credit by the American Academy of Family Physicians. Term of approval begins 10/18/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 0.5 contact hours of continuing education (which includes 0.25 hrs of pharmacology).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure is provided below.

Gerald W. Dryden, MD, MSPH, MSc, AGAF, FASGE,Course Director, has the follow to disclose: serves on the speaker’s bureaus of Abbvie, Takeda, EnteraHeatlh and Salix. Dr. Dryden also conducts contracted research for Abbvie, Johnson & Johnson, Merck, Takeda, Pfizer, and Genetech.

Planning Committee
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.

Harvey Parker, PhD, has no real or apparent conflicts of interest to report.

Josh Kilbridge has no real or apparent conflicts of interest to report.
Commercial Support
This educational activity is supported by an educational grant from Shire.